riociguat   Click here for help

GtoPdb Ligand ID: 5257

Synonyms: Adempas® | BAY 63-2521
Approved drug PDB Ligand
riociguat is an approved drug (FDA (2013), EMA (2014))
Compound class: Synthetic organic
Comment: Riociguat is the first-in-class stimulator of soluble guanylate cyclase (sGC) class of drugs.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 138.07
Molecular weight 422.16
XLogP 2.34
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC(=O)N(c1c(N)nc(nc1N)c1nn(c2c1cccn2)Cc1ccccc1F)C
Isomeric SMILES COC(=O)N(c1c(N)nc(nc1N)c1nn(c2c1cccn2)Cc1ccccc1F)C
InChI InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
InChI Key WXXSNCNJFUAIDG-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Riociguat is approved to treat persistent or recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. This drug was approved following assessment within the US FDA orphan and priority review process.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Riociguat activates soluble guanylyl cyclase (sGC), a heterodimeric enzyme comprising α and β chains. The genes and proteins for the enzyme subunits are listed in this database, in the Soluble guanylyl cyclase family. sGC is a receptor for nitric oxide (NO), activation of which increases biosynthesis of cyclic GMP and this leads to vasodilation.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)